Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 989 Neoplasms 848 Carcinoma, Non-Small-Cell Lung 842 Prostatic Neoplasms 527 Neoplasm Metastasis 500 Leukemia, Myeloid, Acute 488 Melanoma 453 Colorectal Neoplasms 446 Multiple Myeloma 440 Lung Neoplasms 419 Pancreatic Neoplasms 352 Recurrence 350 Lymphoma 349 Ovarian Neoplasms 341 Lymphoma, Non-Hodgkin 327 Leukemia 323 Leukemia, Lymphocytic, Chronic, B-Cell 301 Precursor Cell Lymphoblastic Leukemia-Lymphoma 271 Carcinoma, Renal Cell 256 Head and Neck Neoplasms 246 Brain Neoplasms 243 Carcinoma, Hepatocellular 234 Squamous Cell Carcinoma of Head and Neck 231 Glioblastoma 231 Myelodysplastic Syndromes 229 Lymphoma, Large B-Cell, Diffuse 228 Lymphoma, Follicular 219 Colonic Neoplasms 191 Stomach Neoplasms 182 Rectal Neoplasms 175

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Interventional × Muscle-invasive Bladder Cancer × Clear all

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡